lifestyle.thriveinsider.com

Author: Amneal Pharmaceuticals LLC

Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

April 20, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

April 20, 2026
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

April 14, 2026
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

April 9, 2026
Amneal to Report First Quarter 2026 Results on May 1, 2026

April 7, 2026
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month

April 7, 2026
Amneal to Participate in Upcoming Investor Conference

March 5, 2026
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

February 27, 2026
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

January 28, 2026
Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

January 27, 2026